Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 16;29(11):2919–2928. doi: 10.1038/s41591-023-02603-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 3 — *Randomization was stratified by type 2 diabetes status and by history of documented atherosclerotic cardiovascular disease. The first 30 patients enrolled in the MAESTRO-NAFLD-1 trial were enrolled in the open-label 100 mg resmetirom (including any patients taking thyroxine >75 mcg). After the first 30 patients were enrolled in the open-label 100 mg resmetirom arm, subsequent patients were randomized 1:1:1:1 to 3 double-blind arms (100 mg resmetirom, 80 mg resmetirom, or placebo) or the open-label 100 mg resmetirom arm. Randomization to the open-label arm was discontinued when the target number of patients was achieved (July 1, 2020). Thereafter, eligible patients were randomized 1:1:1 to the 3 double-blind arms (100 mg resmetirom, 80 mg resmetirom, or placebo).